DGAP-News

Vita 34 AG: Positive Development of Business in the First Nine Months of 2014

DGAP-News: Vita 34 AG / Key word(s): 9-month figures
Vita 34 AG: Positive Development of Business in the First Nine Months
of 2014

23.10.2014 / 07:58

---------------------------------------------------------------------

Vita 34 AG: Positive Development of Business in the First Nine Months of
2014

- Earnings before interest, taxes, depreciation and amortization (EBITDA)
rises to EUR 1.6 million; EBITDA margin improves to 16.3 percent

- Earnings before interest and taxes (EBIT) increased by 25.8 percent to
EUR 0.8 million

- Introduction of umbilical cord tissue storage throughout Germany and in
European markets advanced

Leipzig, 23 October 2014 - Vita 34 AG (WKN A0BL84), a pioneer in the
storage of stem cells from umbilical cord blood and tissue, and a
specialist in cryo-preservation, published its financial figures as of
September 30, 2014 today. Overall the company was able to confirm the
positive trend in fiscal year 2014 and further increase profitability.

Earnings before interest, taxes, depreciation and amortization (EBITDA)
increased to EUR 1.6 million in the first nine months, following EUR 1.5
million in the prior year's period. Measured on revenues Vita 34 earned an
EBITDA margin of 16.3 percent (prior year: 15.5 percent). EBIT also
increased and was EUR 0.8 million (prior year: EUR 0.7 million). Among
other factors, the successfully implemented optimization measures in
marketing and sales contributed to the increase in profitability, such that
these expenditures, which were EUR 3.5 million the prior year, were reduced
to EUR 3.3 million. The period result improved to EUR 0.4 million following
EUR 0.3 million in the 2013 reference period. This corresponds to earnings
per share of EUR 0.16 (prior year: EUR 0.11).

In the first nine months of 2014 the total operating income was EUR 10.8
million, following EUR 10.6 million in the prior year. Revenues, increased
from EUR 9.9 million to EUR 10.1 million. Here, Vita 34 was able to post
increases in both business segments: Whereas in the core segment Stem Cell
Banking revenues increased to some EUR 9.7 million (prior year: EUR 9.6
million), the Leipzig company achieved some EUR 0.4 million in the
Biotechnology segment (prior year: EUR 0.3 million).

Dr. André Gerth, Chairman of the Management Board at Vita 34 AG, was
pleased with the profit earned and development of the company: "With
increased revenues and an optimized cost structure, we have been successful
in increasing our profitability. The EBITDA margin of 16.3 percent